Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Trial will not start until FDA approves the supplement that CAPR submitted requesting an additional 20 patients added to the already 20 that they approved. So we will have 40 patients for this trial, 20 on CAPR-1002 and 20 on a Placebo. This will give CAPR the blind study. Just a few things that I remembered from the CC pot. So we should be getting a PR stating FDA approved additional 20 patients in the next coming weeks.
That is correct, they have not. They submitted a revised P2 to FDA to include 20 additional patients that they may use a placebo on. So in total they will treat 40 patients 20 with CAP-1002 AND 20 placebo. This will be a controlled trial so very smart and great news from the company. We will see great gains as the weeks progress.
20 patients have not even been treated yet.
From Volcano yesterday.
Nick Cordero, Broadway star, just came out of a coma today at Cedars Sinai Hospital after 40 days, he was very close to death. The same hospital Capricor tested the 6 COVID-19 patients. Could he be the 6th patient treated with CAP 1002 that remained in critical condition per the announcement 2 weeks ago? If he was, get ready for mainstream media for Capricor for a therapeutic that brought the biggest star yet to have COVID back from the literal abyss. Bullish
$CAPR
Maybe referencing this?
https://www.cedars-sinai.org/newsroom/covid-19-patients-improve-after-heart-cell-therapy/
$GNUS Gof clap with a hat tip! Nice play.
$TRNX
If you want to keep your shares of TRNX to trade, then consider transferring your brokerage account from Robinhood to Webull. You will get free shares for opening an account and also get to trade from 4 am til 8pm at no extra cost. Downside, might take 5-7 business days.
$CAPR Good call. Will add down here too.
https://musculardystrophynews.com/cap-1002-for-dmd/
Hope this helps a bit.
$CAPR absolutely doable. Let's go CAPR!
$CAPR 8k
Positive HOPE-2 TRIAL topline results.
$CAPR NEWS OUT!
$CAPR NEWS OUT!
$CRC Let's break that $3.25 today.
EXPLODE IT DID. HUGE ERUPTION! Another great call. Hats off to you
Damn, awesome trade! Or trades!? ;)
$CRC Great update!
$CRC My pleasure and let's see that push to $3.25++
$CRC Estimated to be on May 07,2020 as per NASDAQ.
About Seanergy Maritime Holdings Corp.
Seanergy Maritime Holdings Corp. is the only pure-play Capesize ship-owner publicly listed in the US. Seanergy provides marine
****dry bulk transportation****services
through a modern fleet of 10 Capesize vessels, with a cargo-carrying capacity of approximately 1,748,581 dwt and an average fleet age of approximately 11 years
$SHIP OFFERING
50,000,000 shares
It will drop and pop just like on the last offering.
$SHIP
Seanergy Maritime Holdings Corp. (the “Company”) (NASDAQ: SHIP) announced today the pricing of an underwritten public offering of 35,290,000 units at a price of $0.17 per unit. Each unit consists of one common share (or pre-funded warrant in lieu of one common share) and one Class D warrant to purchase one common share, and will immediately separate upon issuance. The gross proceeds of the offering to the Company, before underwriting discounts and commissions as well as estimated offering expenses, are expected to be approximately $6.0 million. The Company intends to use the net proceeds of the offering for general corporate purposes
Thank You AF
$MRNA up AH @ $32
MRNA hit $32 AH
$UNT .48 !
Boom .43 $UNT
Nice! TY for the correction. Tomorrow is looking good.
Common stock offered by us Shares of our common stock having an aggregate offering price of up to $25,000,000.Manner of Offering “At the market offerings” that may be made from time to time through our sales agent, JMP. See “Plan of Distribution” on page S-16 of this prospectus supplement.
Common stock to be outstanding
immediately after this offering
12,362,757 shares, assuming sales at a price of $8.30 per share, which was the last reported sale price of our common stock on February 12, 2020.Use of proceeds We currently intend to use the net proceeds from this offering for preparatory commercial activities for the potential commercial launch of IV meloxicam, pipeline development activities, and general corporate purposes. See “Use of Proceeds.”Risk Factors An investment in our common stock involves a high degree of risk. See “Risk Factors” beginning on page S-5 of this prospectus supplement and page 7 of the accompanying prospectus and the similarly titled sections in the documents incorporated by reference into this prospectus supplement.The Nasdaq Capital Market symbol BXRX
The number of shares of our common stock to be outstanding immediately after this offering is based on 9,350,709 shares of our common stock outstanding as of December 31, 2019, and excludes:
•
643,879 shares of our common stock issuable upon the exercise of stock options outstanding as of December 31, 2019 at a weighted- average exercise price of $6.33 per share;
•
1,380,030 shares of our common stock issuable upon the vesting and settlement of restricted stock units outstanding as of December 31, 2019; and
•
1,443,626 shares of our common stock available for future issuance as of December 31, 2019 under our 2019 Equity Incentive Plan.
Video of the year! Love it!
You mean sell my shares for a profit and flip again! Will do.
To start the dilution process over again. Over and over and over.
Its OVER!
Contract Balances
The timing of revenue recognition may differ from the timing of payment by customers. The Company records a receivable when revenue is recognized prior to payment and there is an unconditional right to payment. Alternatively, when payment precedes the provision of the related services, the Company records deferred revenue until the performance obligations are satisfied. The Company had deferred revenue of approximately $0 and $0 as of March 31, 2019 and 2018. The Company expects to satisfy its remaining performance obligations for these services and recognize the deferred revenue and related contract costs over the next twelve months.
The following table represents external net sales disaggregated by product category for the quarter ended March 31,
2019 2018 Gas sold $2,912,877 $869,829 Equipment rentals 869,574 190,309 Equipment sales 1,053,122 111,616 Other 77,758 - Total Revenues from Customers 4,913,332 1,171,753
I believe in there 10-q it states that they own a welding company. Most likely selling gas to themselves. Revenue on gas sales over $2 million
Taronis Generates $1.85 Million in June 2019 Revenues and Record Quarterly Sales
Represents 111% Year-Over-Year Growth
PHOENIX, AZ / ACCESSWIRE / July 11, 2019 / Taronis Technologies, Inc., ("Taronis" or "the Company") (NASDAQ:TRNX), a leading clean technology company in the renewable resources and environmental conservation industry, today announced June sales of $1.85 million. This represents 111% growth when compared to June 2018 sales of just under $0.875 million.
For the second quarter, the Company generated a Company record of $6.06 million of sales, which was 107% higher than the $2.9 million of sales reported for the same period in 2018. Sales growth has also been steadily accelerating, as the second quarter sales were approximately 20% higher than the $4.9 million reported for the first quarter of 2019.
ADVERTISING
inRead invented by Teads
"Our team has been doing an excellent job growing our revenues," commented Scott Mahoney, CEO of Taronis. "We faced several challenges to revenue growth during the quarter. First, there has been a national shortage of helium, and this has caused us to lose several meaningful accounts in the southern California market. Additionally, we experienced a moderate seasonal slowdown in several of our markets which is typical during the peak summer months."
"Historically, we would experience double digit decreases in sales from May to June. For example, in 2017 our June sales were 21% lower than in May due to seasonality. In 2018, our sales were almost 13% lower in June than in May. This year, our ability to drive new client growth offset much more of our seasonality, and we only saw a 9% change from May to June," continued Mr. Mahoney.
"We are effectively leveraging our MagneGas product to gain new clients, conduct field demonstrations, and generate interest in our products and our Company. Our team is using this process to drive results, and we are optimistically looking forward to a very productive third quarter," concluded Mr. Mahoney.
Additional sales growth details are as follows:
The Company experienced the highest year-over-year growth in the Texas-Louisiana market. Sales for the month of June for this region were just over $0.8 million. Sales increased almost 4.5x over the same period last year, as the Company has made a series of acquisitions that now make it one of the largest independent industrial gas distributors in the region.
The Company also experienced rapid year-over-year growth in June in the California market, which generated just under $0.8 million sales for. This represents approximately 65% growth compared to June of 2018, which was largely the result of the acquisition of Complete Welding in Los Angeles in February of this year. This area has been most affected by the national shortage of helium. The Company has identified a potential supply solution, and this could beneficially impact revenues for the Los Angeles market as early as August of 2019.
In the Florida market, sales were just over $0.25 million in May, largely unchanged when compared to the prior year. The Company is expected to launch its fully operational fill plant operations in Clearwater, Florida at the beginning of July. With this new capability, the Florida market has identified almost $2.0 million in potential new client opportunities that the Company could now effectively compete for against the largest distributors in the region. Management believes this development could have a significant impact on the Florida market's outlook for growth going forward.
About Taronis Technologies, Inc.
Taronis Technologies, Inc. ( TRNX ) owns a patented plasma arc technology that enables two primary end use applications for fuel generation and water decontamination.
The Company's fuel technology enables a wide use of hydrocarbon feedstocks to be readily converted to fossil fuel substitutes. The Company is developing a wide range of end market uses for these fuels, including replacement products for propane, compressed natural gas, and liquid natural gas. The Company currently markets a proprietary metal cutting fuel that is highly competitive with acetylene. The Company distributes its proprietary metal cutting fuel through Independent Distributors in the US and through its wholly owned distributors doing business as "MagneGas Welding Supply". The Company operates 22 locations across California, Texas, Louisiana, and Florida.
The Company's technology can also be implemented for the decontamination of waste water, including sterilizing water, eradicating all pathogens. The technology is being tested to determine if it can completely eliminate pharmaceutical contaminants such as antibiotics, hormones, and other soluble drugs suspended in contaminated water. Lastly, the technology process is capable of reducing or eliminating other contaminants, such as harmful metals, as well as nitrogen, phosphorus, and potassium levels that trigger toxic algae blooms. The technology has prospective commercial applications in the agricultural, pharmaceutical, and municipal waste markets. For more information on Taronis, please visit the Company's website at http://www.TaronisTech.com ;.
Taronis also owns a controlling interest in Water Pilot, LLC. The WATER PILOT® System immediately reduces water consumption and provides you with live remote consumption monitoring for long term leak protection and water asset management. An integral, client based alarm and notification system that reports to any mobile device. Water Pilot may be appropriate for a wide range of businesses or properties with a water meter. For more information, please visit our website at www.gowaterpilot.com/
FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements as defined within Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements relate to future events, including our ability to raise capital, or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity. We assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.
For a discussion of these risks and uncertainties, please see our filings with the Securities and Exchange Commission. Our public filings with the SEC are available from commercial document retrieval services and at the website maintained by the SEC at http://www.sec.gov.
SOURCE:Taronis Technologies, Inc.